1. Home
  2. ELEV vs LEXX Comparison

ELEV vs LEXX Comparison

Compare ELEV & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELEV
  • LEXX
  • Stock Information
  • Founded
  • ELEV 2019
  • LEXX 2004
  • Country
  • ELEV United States
  • LEXX Canada
  • Employees
  • ELEV N/A
  • LEXX N/A
  • Industry
  • ELEV Biotechnology: Pharmaceutical Preparations
  • LEXX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELEV Health Care
  • LEXX Health Care
  • Exchange
  • ELEV Nasdaq
  • LEXX Nasdaq
  • Market Cap
  • ELEV 37.6M
  • LEXX 38.9M
  • IPO Year
  • ELEV 2021
  • LEXX N/A
  • Fundamental
  • Price
  • ELEV $0.58
  • LEXX $2.23
  • Analyst Decision
  • ELEV Strong Buy
  • LEXX Strong Buy
  • Analyst Count
  • ELEV 5
  • LEXX 2
  • Target Price
  • ELEV $7.20
  • LEXX $11.00
  • AVG Volume (30 Days)
  • ELEV 860.8K
  • LEXX 202.7K
  • Earning Date
  • ELEV 11-06-2024
  • LEXX 01-10-2025
  • Dividend Yield
  • ELEV N/A
  • LEXX N/A
  • EPS Growth
  • ELEV N/A
  • LEXX N/A
  • EPS
  • ELEV N/A
  • LEXX N/A
  • Revenue
  • ELEV N/A
  • LEXX $464,278.00
  • Revenue This Year
  • ELEV N/A
  • LEXX $20.39
  • Revenue Next Year
  • ELEV N/A
  • LEXX $113.25
  • P/E Ratio
  • ELEV N/A
  • LEXX N/A
  • Revenue Growth
  • ELEV N/A
  • LEXX 105.24
  • 52 Week Low
  • ELEV $0.44
  • LEXX $1.20
  • 52 Week High
  • ELEV $5.83
  • LEXX $6.85
  • Technical
  • Relative Strength Index (RSI)
  • ELEV 43.94
  • LEXX 47.23
  • Support Level
  • ELEV $0.60
  • LEXX $2.00
  • Resistance Level
  • ELEV $0.70
  • LEXX $2.54
  • Average True Range (ATR)
  • ELEV 0.08
  • LEXX 0.24
  • MACD
  • ELEV -0.01
  • LEXX -0.00
  • Stochastic Oscillator
  • ELEV 7.67
  • LEXX 27.06

About ELEV Elevation Oncology Inc. Common stock

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: